Biểu đồ giá cổ phiếu PASG
PASG Dự đoán giá cổ phiếu
Passage Bio Inc
$5.59
4.87%
$0.25
Khi đóng cửa: Jun 18, 16:00:00 GMT-4
$5.59
0%
$0
Phiên trước giờ: Jun 22, 05:10:09 GMT-4
Quay lại
Passage Bio Inc (PASG) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$5.33
Giá mở cửa
$5.34
Phạm vi ngày
$5.27 - $5.65
Phạm vi 52 tuần
$3.93 - $20
Khối lượng
73.0K
Khối lượng trung bình
68.6K
Tỷ suất cổ tức
--
EPS (TTM)
-11.84
Vốn hóa thị trường
$17.9M
PASG là gì?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.
